FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to fused proteins with an albumin-binding domain (hereinafter – ABD); it can be used for recombinant production of fused protein with ABD. Fused protein with ABD is obtained in a recombinant way, in which ABD is attached to one or several fusing partners, and it contains vhCDR1, vhCDR2, vhCDR3 of a heavy chain of SEQ ID NO: 25 and vlCDR1, vlCDR2, vlCDR3 of a light chain of SEQ ID NO: 29.
EFFECT: invention provides obtainment of fused protein, which shows increased half-life, improved pharmacokinetics in vivo compared to biological preparations without ABD, and increased localization in tumor.
22 cl, 51 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IL-17A-BINDING POLYPEPTIDES | 2016 |
|
RU2749712C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| POLYPEPTIDES RECRUITING T-CELLS, CAPABLE OF BINDING CD123 AND ALPHA/BETA TCR | 2017 |
|
RU2775063C2 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| IMPROVED IMMUNOGLOBULIN VARIABLE DOMAINS | 2015 |
|
RU2809788C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| BISPECIFIC ANTIBODIES | 2020 |
|
RU2818588C2 |
